Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISTARIL vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Anxiety and tension associated with psychoneurosis,Pruritus due to allergic conditions (e.g., urticaria, atopic dermatitis),Sedation prior to dental or surgical procedures,Nausea and vomiting (off-label)
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include cetirizine.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Highly protein-bound: approximately 89-93%, primarily to albumin.
99% (primarily albumin and alpha-1-acid glycoprotein).
Volume of distribution: 7-10 L/kg, indicating extensive tissue distribution.
2.4 L/kg (high tissue distribution, including ocular tissues).
Oral: incomplete bioavailability due to first-pass metabolism, estimated at 40-60%; IM: nearly complete (85-100%).
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
No specific adjustment; use with caution in severe renal impairment due to potential accumulation of metabolites.
No dosage adjustment required based on renal function; systemic absorption is minimal.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 50 mg per dose (≤12 years); IM: 0.5-1 mg/kg every 4-6 hours.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Start at lower end of dosing range (e.g., 25 mg oral 3-4 times daily); monitor for sedation and anticholinergic effects.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
No FDA black box warning.
None
May cause QT prolongation; use with caution in patients with risk factors (e.g., electrolyte imbalance, concomitant QT-prolonging drugs),Sedation and impaired cognitive/motor function; avoid driving or hazardous activities,Anticholinergic effects (e.g., urinary retention, constipation); use cautiously in elderly or patients with prostatic hypertrophy,Respiratory depression with concurrent CNS depressants,Use in pregnancy: avoid especially during early pregnancy; may increase risk of fetal abnormalities
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester),Porphyria,Breastfeeding (use caution)
Hypersensitivity to ketotifen or any component of the product.
Alcohol increases sedation and CNS depression; avoid concurrent use. No significant food interactions, but take with food if GI upset occurs.
None reported.
First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal withdrawal symptoms (irritability, tremors) with chronic maternal use near term; no evidence of structural anomalies.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Hydroxyzine is excreted in human milk; M/P ratio not established. Potential for adverse effects in infants (sedation, irritability). Use during breastfeeding only if clearly needed; monitor infant for drowsiness.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No specific dose adjustments recommended in pregnancy; use lowest effective dose. Hydroxyzine may be less effective if used as an antiemetic due to altered clearance; consider alternative agents.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
VISTARIL (hydroxyzine pamoate) is a first-generation antihistamine with anxiolytic and sedative properties. It is often used for preoperative sedation, pruritus, and anxiety. Onset of sedation is rapid (15-30 minutes) but duration is short (4-6 hours). It has anticholinergic effects; caution in elderly and patients with glaucoma or prostatic hypertrophy. Do not administer intra-arterially or subcutaneously (risk of hemolysis or tissue necrosis). It is not a controlled substance, but has abuse potential. May cause significant somnolence; advise against driving or operating machinery.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Take as prescribed; do not exceed recommended dose.,May cause drowsiness; avoid driving or heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of allergic reaction (rash, difficulty breathing) immediately.,Do not stop abruptly without consulting doctor.,Store at room temperature away from moisture and heat.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISTARIL vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
VISTARIL is a Antihistamine that works by Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISTARIL and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISTARIL is: Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISTARIL and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISTARIL is classified as Category C. First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal w. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.